OSTEOPOROSIS IN HYPERCALCURIC KIDNEY STONE FORMERS

高钙肾结石形成者的骨质疏松症

• 批准号: 6298905
• 负责人: JOHN R ASPLIN
• 金额: $ 10万
• 依托单位: LITHOLINK CORPORATION
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-04-15 至 2001-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6298905
• 关键词: artificial intelligence; bone density; clinical research; computer program /software; computer system design /evaluation; disease /disorder proneness /risk; human population study; human subject; hypercalciuria; nephrocalcinosis; nephrolithiasis; osteoporosis; photon absorptiometry

DESCRIPTION (Adapted from the Applicant's Abstract): The aim of our research is to determine the risk of bone disease in hypercalcuric kidney stone formers and their families by establishing an algorithm that takes into account bone mineral density (BMD), demographic characteristics, diet history, and urine chemistries, including markers of bone turnover. This algorithm will allow us to determine which hypercalcurics need clinical evaluation for osteoporosis and will form the basis of a disease management product. In the process of creating this algorithm, we will be the first to determine the prevalence of bone disease in hypercalcuric stone formers and their families and over time make some estimates of incidence rates. A longer-term goal of our research is to study the genetic underpinnings of osteoporosis and nephrolithiasis. PROPOSED COMMERCIAL APPLICATION: Litholink provides disease managment services for kidney stone patients. We hope to use the algorithm developed in this research to expand our services to include bone disease management in kidney stone forming patients and their families.

描述（改编自申请人的摘要）：我们研究的目的是 确定高钙肾结石患者发生骨病的风险， 通过建立一种算法， 矿物质密度（BMD）、人口统计学特征、饮食史和尿液 化学物质，包括骨转换的标志物。这个算法可以让我们 以确定哪些高钙剂需要骨质疏松症的临床评价， 将成为疾病管理产品的基础。过程中所创造的 这个算法，我们将是第一个确定骨的患病率， 高钙结石患者及其家人的疾病， 对发病率的一些估计。我们研究的长期目标是 研究骨质疏松症和肾结石的遗传基础。 拟定商业应用： Litholink为肾结石患者提供疾病管理服务。 我们希望 使用本研究中开发的算法来扩展我们的服务， 肾结石患者及其家属的疾病管理。